WebbЦена акций, фундаментальный анализ и пошаговое руководство по покупке акций Phio Pharmaceuticals Corp. (PHIOW) без уплаты комиссионных WebbPHIO - Short Interest - Phio Pharmaceuticals Corp Stock - Short Squeeze, Borrow Rates EXTENDED Overview Owners Insiders Short Interest Options Filings Financials Dividends Earnings Forecast Introduction This short interest tracker provides a variety of short interest related data, sourced from a variety of partners.
Phio Pharmaceuticals Company Profile: Stock Performance
Webb25 jan. 2024 · MARLBOROUGH, Mass., Jan. 25, 2024-- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that the Company's Board of Directors has approved a reverse … WebbDisclaimer: This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. lithd news
Phio Pharmaceuticals Corp.(PHIOW)其他公告 - 富途牛牛
WebbUNDERWRITER COMMON STOCK PURCHASE WARRANT PHIO Pharmaceuticals Corp. Document Metadata. Filed: January 31st, 2024. Country United States; Jurisdiction New York; Industry Pharmaceutical preparations; Company Phio Pharmaceuticals Corp. SEC Filing ID 0001683168-20-000317; SEC Filing Type s-1-a; SEC Exhibit ID ex-4; Webb14 nov. 2024 · The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Phio Pharmaceuticals with a $6.00 average price target. See Insiders’ Hot Stocks on TipRanks >> Webb8 apr. 2024 · Phio Pharmaceuticals Corp. (NASDAQ: PHIO) By EOD on April 8th, shares of PHIO stock had shot up by over 159% as well as a 3% after-hours gain. This is a staggering uptick and one that reflects news that came out only a few hours earlier. At around 1 P.M. on Friday, April 8th, Phio announced new positive data regarding its PH-894 RNAi … impp therapie